NCT06595160 Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
| NCT ID | NCT06595160 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emory University |
| Condition | Borderline Resectable Pancreatic Ductal Adenocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 87 participants |
| Start Date | 2024-08-05 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 87 participants in total. It began in 2024-08-05 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study explores the relationship between pre-treatment dietary patterns, fecal microbiome, and response to chemotherapy in patients with pancreatic ductal adenocarcinoma.
Eligibility Criteria
Inclusion Criteria: * \* Age ≥ 18 years with signed informed consent form * Patients must have a histological diagnosis of PDAC * Resectable or borderline resectable PDAC on imaging Exclusion Criteria: * \* Patients with locally advanced and metastatic stage IV PDAC * Patients who have already received or completed neoadjuvant chemotherapy for PDAC * Patients with active malignancy receiving systemic therapy
Contact & Investigator
Mihir M Shah
PRINCIPAL INVESTIGATOR
Emory University Hospital/Winship Cancer Institute
Frequently Asked Questions
Who can join the NCT06595160 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Borderline Resectable Pancreatic Ductal Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06595160 currently recruiting?
Yes, NCT06595160 is actively recruiting participants. Contact the research team at mihir.m.shah@emory.edu for enrollment information.
Where is the NCT06595160 trial being conducted?
This trial is being conducted at Atlanta, United States.
Who is sponsoring the NCT06595160 clinical trial?
NCT06595160 is sponsored by Emory University. The principal investigator is Mihir M Shah at Emory University Hospital/Winship Cancer Institute. The trial plans to enroll 87 participants.